• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why CommScope Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Monday's Mid-Day Session

    1/22/24 1:08:22 PM ET
    $ACRS
    $ADM
    $AFRM
    $AGFY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Packaged Foods
    Consumer Staples
    Get the next $ACRS alert in real time by email

    Shares of CommScope Holding Company, Inc. (NASDAQ:COMM) fell sharply during Monday’s session.

    B of A Securities analyst Tal Liani downgraded CommScope from Neutral to Underperform and lowered the price target from $2.1 to $2.

    CommScope shares dipped 6.9% to $2.2150 on Monday.

    Here are some other stocks moving in today's mid-day session.

    Gainers

    • Sagimet Biosciences Inc. (NASDAQ:SGMT) shares jumped 135% to $15.99 after the company announced denifanstat in the Phase 2b FASCINATE-2 clinical trial achieved statistically significant results on the primary and multiple secondary endpoints.
    • Rail Vision Ltd. (NASDAQ:RVSN) surged 54.5% to $2.1173. Rail Vision said its main line system has successfully obtained formal certifications for critical European Union railway standards.
    • Tenaya Therapeutics, Inc. (NASDAQ:TNYA) gained 40% to $5.36.
    • Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) jumped 37% to $6.70.
    • Lytus Technologies Holdings PTV. Ltd. (NASDAQ:LYT) surged 34.1% to $0.1376.
    • Fisker Inc. (NYSE:FSR) shares gained 32.4% to $1.0450. Fisker filed a Form 8-K with the Securities and Exchange Commission regarding amendments with its 2025 convertible notes investor.
    • Fitell Corporation (NASDAQ:FTEL) gained 28.5% to $2.25.
    • Rumble Inc. (NASDAQ:RUM) surged 25.6% to $4.51 after the company announced a partnership with Barstool Sports.
    • Eightco Holdings Inc. (NASDAQ:OCTO) jumped 24.9% to $0.5641.
    • Digital World Acquisition Corp. (NASDAQ:DWAC) rose 24% to $32.70 after Ron DeSantis ended his presidential campaign. Digital World Acquisition Corp is the business combination partner of Trump Media & Technology Group.
    • Fresh2 Group Limited (NASDAQ:FRES) gained 22.5% to $0.4900.
    • Taoping Inc. (NASDAQ:TAOP) rose 21.3% to $1.0298.
    • Coherus BioSciences, Inc. (NASDAQ:CHRS) shares climbed 17.1% to $2.8577 after the company announced an agreement to divest ophthalmology franchise to Sandoz in $170 million upfront all cash deal.
    • ChargePoint Holdings, Inc. (NYSE:CHPT) rose 16.3% to $2.0250.
    • CXApp Inc. (NASDAQ:CXAI) gained 15% to $1.3098.
    • NuStar Energy L.P. (NYSE:NS) rose 14.2% to $20.59 after Sunoco announced it will acquire the company in an all-equity transaction valued at roughly $7.3 billion.
    • Upstart Holdings, Inc. (NASDAQ:UPST) gained 13.3% to $37.06.
    • Spirit Airlines, Inc. (NYSE:SAVE) climbed 12.6% to $7.53 after the company and JetBlue Airways announced Friday that they will appeal a ruling blocking their proposed merger.
    • Affirm Holdings, Inc. (NASDAQ:AFRM) rose 11.3% to $46.98.
    • Fastly, Inc. (NYSE:FSLY) gained 10.3% to $20.69 after Citigroup upgraded the stock from Sell to Neutral and raised its price target from $11 to $20.
    • Aclaris Therapeutics, Inc. (NASDAQ:ACRS) gained 7% to $1.22. Aclaris Therapeutics recently announced leadership changes as the company undertakes a strategic review of its business.
    • Genius Group Limited (NYSE:GNS) shares gained 6.4% to $0.3110 after gaining around 9% on Friday. Genius Group recently announced closing of $8.25 million public offering.
    • StoneCo Ltd. (NASDAQ:STNE) rose 5.7% to $18.00. Goldman Sachs analyst Tito Labarta upgraded StoneCo from Neutral to Buy and raised the price target from $12 to $21.

    Losers

    • Virios Therapeutics, Inc. (NASDAQ:VIRI) shares fell 39.2% to $0.4928. Virios Therapeutics announced plans to advance development of IMC-2 as treatment for symptoms associated with long-COVID.
    • Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) fell 30.9% to $3.11. Processa Pharmaceuticals recently announced plans to expand the development of Next Generation Capecitabine into the treatment of advanced or metastatic breast cancer.
    • Nuvve Holding Corp. (NASDAQ:NVVE) fell 25.8% to $2.85. Nuvve recently announced a 1-for-40 reverse stock split.
    • Hongli Group Inc. (NASDAQ:HLP) dipped 25.7% to $2.45.
    • Agrify Corporation (NASDAQ:AGFY) shares fell 19.8% to $0.8495 after declining around 23% on Friday. Agrify recently entered into a multi-million dollar sales agreement with Ocean Deep/Golden Lake Business Park.
    • NexImmune, Inc. (NASDAQ:NEXI) declined 19.4% to $5.64.
    • Archer-Daniels-Midland Company (NYSE:ADM) fell 19.1% to $55.17 amid the company placing its CFO on leave due to an investigation studying accounting practices and procedures related to the company's nutrition segment. ADM said it now expects an adjusted earnings per share of $6.90 for the fiscal year ended Dec. 2023.
    • Calidi Biotherapeutics, Inc. (NASDAQ:CLDI) dipped 18% to $0.91
    • Treasure Global Inc. (NASDAQ:TGL) shares fell 17.2% to $0.0929 after gaining 9% on Friday.
    • MMTec, Inc. (NASDAQ:MTC) fell 14.6% to $2.09.
    • Intelligent Bio Solutions Inc. (NASDAQ:INBS) declined 13.4% to $0.2979. Intelligent Bio Solutions said that DGP Plc has selected the revolutionary portable intelligent fingerprinting drug screening system to enable in-house drug testing.
    • WiSA Technologies, Inc. (NASDAQ:WISA) shares dipped 11.7% to $0.0940 after declining over 3% on Friday.
    • C3is Inc. (NASDAQ:CISS) fell 11.1% to $0.1202 after falling 6% on Wednesday. C3is shares dipped 64% on Friday after the company announced pricing of its $7 million upsized underwritten public offering.
    • Airspan Networks Holdings Inc (NASDAQ:MIMO) declined 10.3% to $0.1895 after surging 24% on Friday. Airspan recently announced a partnership with GCT Semiconductor to develop an RF module.
    • B. Riley Financial, Inc. (NASDAQ:RILY) shares dipped 10.1% to $18.14. B. Riley Financial is reportedly facing a probe by U.S. authorities over its dealings with Brian Kahn, a key client linked to securities fraud, and the utilization of his assets to secure a loan from Nomura Holdings.
    • Gilead Sciences, Inc. (NASDAQ:GILD) fell 9.7% to $78.80 after the company reported its phase 3 study in metastatic non-small cell lung cancer did not meet primary endpoints.
    • e.l.f. Beauty, Inc. (NYSE:ELF) declined 6.5% to $147.62. Morgan Stanley analyst Dara Mohsenian downgraded e.l.f. Beauty from Overweight to Equal-Weight and raised the price target from $137 to $168.
    • Worthington Enterprises, Inc. (NYSE:WOR) fell 5% to $52.47. Goldman Sachs analyst Susan Maklari initiated coverage on Worthington Enterprises with a Sell rating and announced price target of $50.

     

    Now Read This: How To Earn $500 A Month From 3M Stock Ahead Of Q4 Earnings Print

    Get the next $ACRS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACRS
    $ADM
    $AFRM
    $AGFY

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    Affirm Holdings Inc.
    $AFRM
    2/20/2026$55.00Neutral
    Robert W. Baird
    Upstart Holdings Inc.
    $UPST
    2/17/2026$30.00Sell → Neutral
    Compass Point
    Upstart Holdings Inc.
    $UPST
    2/13/2026$20.00Mkt Perform → Mkt Underperform
    Citizens
    Upstart Holdings Inc.
    $UPST
    2/13/2026$35.00Sell → Neutral
    Goldman
    Fastly Inc.
    $FSLY
    2/12/2026Mkt Perform → Outperform
    William Blair
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    StoneCo Ltd.
    $STNE
    2/9/2026$22.00Buy
    BTIG Research
    More analyst ratings

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Robert W. Baird initiated coverage on Affirm with a new price target

    Robert W. Baird initiated coverage of Affirm with a rating of Neutral and set a new price target of $55.00

    2/20/26 8:23:24 AM ET
    $AFRM
    Finance: Consumer Services
    Finance

    Upstart upgraded by Compass Point with a new price target

    Compass Point upgraded Upstart from Sell to Neutral and set a new price target of $30.00

    2/17/26 8:05:30 AM ET
    $UPST
    Finance: Consumer Services
    Finance

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Farrell Matthew bought $464,814 worth of shares (5,000 units at $92.96), increasing direct ownership by 86% to 10,820 units (SEC Form 4)

    4 - e.l.f. Beauty, Inc. (0001600033) (Issuer)

    2/23/26 4:07:34 PM ET
    $ELF
    Package Goods/Cosmetics
    Consumer Discretionary

    Director Mcatee David R Ii bought $486,720 worth of shares (7,500 units at $64.90) (SEC Form 4)

    4 - Archer-Daniels-Midland Co (0000007084) (Issuer)

    2/9/26 5:27:53 PM ET
    $ADM
    Packaged Foods
    Consumer Staples

    Large owner Tether Global Investments Fund, S.I.C.A.F., S.A. bought $4,220,298 worth of shares (777,012 units at $5.43) (SEC Form 4)

    4 - Rumble Inc. (0001830081) (Issuer)

    2/6/26 8:42:27 PM ET
    $RUM
    Computer Software: Programming Data Processing
    Technology

    $ACRS
    $ADM
    $AFRM
    $AGFY
    SEC Filings

    View All

    Aclaris Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Aclaris Therapeutics, Inc. (0001557746) (Filer)

    2/26/26 7:15:27 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Fastly Inc.

    144 - Fastly, Inc. (0001517413) (Subject)

    2/25/26 5:15:57 PM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    SEC Form S-8 filed by Fastly Inc.

    S-8 - Fastly, Inc. (0001517413) (Filer)

    2/25/26 5:12:00 PM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intelligent Bio Solutions Successfully Manufactures and Ships First Readers with New Partner, Accelerating Scale and Driving Gross Margin Expansion in Anticipation of Planned U.S. Entry

    Successful delivery in partnership with Syrma Johari validates manufacturing scale, strengthens commercial readiness, and supports planned U.S. market entry in 2026 Partnership on track to deliver annual production cost savings of more than 40% with expected improvement of approximately 20 percentage points in gross margin annually Doubled in-house lateral flow test strip production capacity strengthens vertical integration, accelerates R&D, and enables panel expansion NEW YORK, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (NASDAQ:INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today a

    2/25/26 8:45:00 AM ET
    $INBS
    Medical/Dental Instruments
    Health Care

    AI-First Businesses are Paying an "AI Speed Tax" when Recovering from Cybersecurity Incidents, according to Fastly's Global Security Research Report

    Fast moving AI adopters are paying the price with 80 day longer recovery times, higher breach costs and expanding attack surfaces Fastly, Inc. (NASDAQ:FSLY), a leader in global edge cloud platforms, today published the findings from its fourth annual Global Security Research Report. It reveals that AI-first businesses – those integrating AI into key processes and offerings from the outset rather than as a secondary enhancement – are paying an AI tax by failing to modernize security in step with AI's rapid expansion across IT infrastructure. These businesses report taking nearly seven months on average to fully recover from cybersecurity incidents, 80 days longer than businesses that do n

    2/25/26 8:00:00 AM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    $ACRS
    $ADM
    $AFRM
    $AGFY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Technology Officer Bergman Artur sold $683,200 worth of shares (40,000 units at $17.08) (SEC Form 4)

    4 - Fastly, Inc. (0001517413) (Issuer)

    2/25/26 5:14:00 PM ET
    $FSLY
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Datta Sanjay sold $238,375 worth of shares (7,982 units at $29.86), decreasing direct ownership by 3% to 276,688 units (SEC Form 4)

    4 - Upstart Holdings, Inc. (0001647639) (Issuer)

    2/24/26 4:47:16 PM ET
    $UPST
    Finance: Consumer Services
    Finance

    Officer Mirgorodskaya Natalia sold $18,925 worth of shares (633 units at $29.90), decreasing direct ownership by 2% to 26,155 units (SEC Form 4)

    4 - Upstart Holdings, Inc. (0001647639) (Issuer)

    2/24/26 4:46:52 PM ET
    $UPST
    Finance: Consumer Services
    Finance

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Leadership Updates

    Live Leadership Updates

    View All

    ChargePoint Appoints Jaser Faruq Chief Product and Software Officer

    ChargePoint (NYSE:CHPT), a global leader in electric vehicle (EV) charging solutions, today announced the appointment of industry veteran Jaser Faruq as Chief Product and Software Officer. In this role, Faruq will lead ChargePoint's global product management and software development teams, bringing to market revolutionary new hardware and software solutions for the future of eMobility. Faruq brings considerable experience to ChargePoint, most recently at Schneider Electric. While there, Faruq led the company's North American electrification businesses, overseeing EV chargers, batteries, and smart panels. Simultaneously, Faruq managed several acquisitions, including that of the energy mark

    2/23/26 4:15:00 PM ET
    $CHPT
    Industrial Specialties
    Consumer Discretionary

    Fitell Corporation Appoints AI and Robotics Executive Jack Zeng as Head of Technology at 2F Robotics to Accelerate Development and Commercialization Strategy

    Sydney, Australia, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Fitell Corporation (NASDAQ:FTEL) ("Fitell" or the "Company") announced today the appointment of Jack Zeng as the Head of Technology of 2F Robotics Pty Ltd, Fitell's robotics-focused subsidiary. Before joining Fitell, Mr. Zeng has founded and scaled successful technology ventures and brought experience in building data analytics and intelligent agent solutions for major enterprise customers including Fortune 500 across Asia, spanning product research and development, deployment, and go-to-market. With a background encompassing top-tier computer science education, Microsoft-certified engineering, and successful AI ventures, he has a track

    2/4/26 8:30:00 AM ET
    $FTEL
    Recreational Games/Products/Toys
    Consumer Discretionary

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Financials

    Live finance-specific insights

    View All

    Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    - Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 - - Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 - - Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 - - ATI-2138, Aclaris' Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model -  WAYNE, Pa., Feb. 26,

    2/26/26 6:58:00 AM ET
    $ACRS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Treasure Global Reports Second Quarter Year 2026 Financial Results

    KUALA LUMPUR, Malaysia, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Treasure Global Inc. (NASDAQ:TGL) ("Treasure Global" or the "Company"), a Southeast Asia–anchored technology company, today announced its financial results for the second quarter ended December 31, 2025. Key Financial Highlights Revenue for the second quarter was USD1.08 million, a significant increase from USD0.30 million in Q2 FY2025, driven by continued growth in gift-card ("E-voucher") transactions on the ZCITY platform.Net loss was USD3.11 million, compared to USD0.23 million in Q2 FY2025, partially offset by USD4.63 million in favorable fair-value adjustments of derivative liabilities.Loss per share was USD(3.47), compared t

    2/24/26 8:35:00 AM ET
    $TGL
    Real Estate

    C3is Inc. reports fourth quarter and twelve months 2025 financial and operating results

    ATHENS, Greece, Feb. 19, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the fourth quarter and twelve months ended December 31, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTS Our handysize dry bulk carriers are on time charters of short-term durations, producing steady cash flows, while our Aframax tanker operates in the spot market, currently achieving voyage charter rates of around $60,000 per day.All of our vessels are unencumbered.Fleet operational utilization of 93.5% for the three months ended December 31, 2025, compar

    2/19/26 9:10:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    $ACRS
    $ADM
    $AFRM
    $AGFY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Hongli Group Inc.

    SC 13G - Hongli Group Inc. (0001855557) (Subject)

    12/12/24 6:49:27 PM ET
    $HLP
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Hongli Group Inc.

    SC 13G - Hongli Group Inc. (0001855557) (Subject)

    12/12/24 6:47:57 PM ET
    $HLP
    Industrial Machinery/Components
    Industrials

    SEC Form SC 13G filed by Hongli Group Inc.

    SC 13G - Hongli Group Inc. (0001855557) (Subject)

    12/12/24 6:45:55 PM ET
    $HLP
    Industrial Machinery/Components
    Industrials